Department of Surgery, Thomas Jefferson University Hospital, 1100 Walnut Street, Suite 500, Philadelphia, PA, 19107, USA.
J Gastrointest Surg. 2017 Sep;21(9):1377-1384. doi: 10.1007/s11605-017-3478-y. Epub 2017 Jun 29.
The effects of neoadjuvant chemoradiation therapy on lymph node retrieval during esophagectomy for patients with esophageal cancer are unclear. The aim of this study was to quantify lymph node retrieval after R0 esophagectomy and to assess its impact on overall survival in induction therapy patients.
One hundred seventy-four consecutive patients underwent esophagectomy with or without induction therapy from 2008 to 2015 for esophageal cancer. Total lymph nodes, positive lymph nodes, and lymph node ratios were compared between two groups of patients: those treated with either upfront surgery or those treated with neoadjuvant chemoradiation therapy followed by surgery. Comparisons were made using Student's t test. Overall survival was obtained and compared using Kaplan Meier survival curves.
Total lymph node counts were less in the induction therapy group (p = 0.027), while positive lymph node counts and lymph node ratios did not differ between groups (p = 0.262 and p = 0.310, respectively). In the neoadjuvant chemoradiation followed by surgery group, overall survival was significantly shorter for patients who had any positive lymph nodes in the pathologic specimen (p = 0.0065).
Total lymph node counts were significantly lower in the induction therapy group, while positive lymph node counts and lymph node ratios did not differ from the upfront surgery group. Although overall survival was not different between groups, it was decreased within the induction therapy cohort among those who had any positive lymph nodes retrieved at surgery. This study confirms that unstratified gross lymph node counts do not substantially relate to prognosis in the heterogeneous population of locally advanced esophageal cancer patients who may or may not have had neoadjuvant chemoradiation.
新辅助放化疗对食管癌患者食管切除术后淋巴结检出的影响尚不清楚。本研究旨在量化 R0 食管切除术后的淋巴结检出数量,并评估其对诱导治疗患者总生存的影响。
2008 年至 2015 年期间,174 例连续接受食管切除术的食管癌患者接受了或未接受诱导治疗。比较两组患者的总淋巴结、阳性淋巴结和淋巴结比例:一组为直接手术治疗,另一组为新辅助放化疗后手术治疗。使用学生 t 检验进行比较。采用 Kaplan-Meier 生存曲线获得并比较总生存情况。
诱导治疗组的总淋巴结计数较少(p=0.027),而阳性淋巴结计数和淋巴结比例在两组之间无差异(p=0.262 和 p=0.310)。在新辅助放化疗后手术组中,病理标本中有任何阳性淋巴结的患者总生存时间明显缩短(p=0.0065)。
诱导治疗组的总淋巴结计数明显较低,而阳性淋巴结计数和淋巴结比例与直接手术组无差异。尽管两组之间的总生存时间无差异,但在接受诱导治疗的患者中,手术中检出任何阳性淋巴结的患者的总生存时间降低。本研究证实,在接受或未接受新辅助放化疗的局部晚期食管癌患者异质人群中,未经分层的大体淋巴结计数与预后无显著相关性。